SLC5A2 and heart failure: Unlike heart failure with reduced ejection fraction (HFrEF) with four life-saving therapies, sodium–glucose cotransporter-2 (SGLT2) inhibitor is the only disease-modifying medication with a class IIa indication for HFpEF, thanks to the success of EMPEROR-Preserved (2021) and DELIVER (2022) trials [5,6,7].